San Fran biotech gets an­oth­er blow to lead drug; Swiss biotech rais­es $49 mil­lion in Se­ries A — with help from big ven­ture

In the wake of Calithera Bio­sciences ax­ing a third of its work­force in Jan­u­ary over a failed Phase II tri­al with lead drug tela­gle­na­s­tat in pa­tients with re­nal cell car­ci­no­ma, they just got slammed with the sec­ond half of a dou­ble wham­my.

The South San Fran­cis­co biotech an­nounced this morn­ing that it is ter­mi­nat­ing an­oth­er Phase II tri­al in­volv­ing the drug — this tri­al had the drug plus stan­dard-of-care chemo be­ing used in pa­tients with NSCLC with ei­ther KEAP1 or NFR2 mu­ta­tions.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN